Cas:13827-62-8 2,6-dichlorosulfonylnaphtalene manufacturer & supplier

Chemical Name:2,6-dichlorosulfonylnaphtalene

CAS.NO:13827-62-8

Synonyms:naphthalene-2,6-disulfonyl chloride;2,6-Naphthalenedisulfonyl dichloride;2,6-dichlorosulfonylnaphtalene

Molecular Formula:C₁₀H₆Cl₂O₄S₂

Molecular Weight:325.188

HS Code:2904909090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:499.4±25.0 °C at 760 mmHg

Density:1.7±0.1 g/cm3

Index of Refraction:1.648

PSA:85.04000

Exact Mass:323.908447

LogP:2.99

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like naphthalene-2,6-disulfonyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,6-dichlorosulfonylnaphtalene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,6-dichlorosulfonylnaphtalene Use and application,naphthalene-2,6-disulfonyl chloride technical grade,usp/ep/jp grade.

Related News: Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 2,6-dichlorosulfonylnaphtalene manufacturer The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 2,6-dichlorosulfonylnaphtalene supplier The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 2,6-dichlorosulfonylnaphtalene vendor The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. 2,6-dichlorosulfonylnaphtalene factory The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward.